IRVINGTON, N.Y., Oct. 25, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed and is commercializing MelaFind®, the first and only FDA approved optical diagnostic device for melanoma detection used by dermatologists in their fight against melanoma, today announced that the company will be participating in the Washington D.C. Dermatological Society's Fall Clinical Conference taking place October 26, 2013 in Falls Church, Virginia. The Washington D.C. Dermatological Society's Fall Clinical Conference is a half-day medical meeting that is well attended by approximately 100 dermatologists, as well as physician assistants and nurse...
↧
MELA Sciences, Inc., a Leader in the Fight Against Melanoma, Participates in the Washington D.C. ...
↧